Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry

Clinical and Experimental Rheumatology

Volumn 35, Issue , 2017, Pages S106-S113

  Chung, Lorinda ^a,b   Fairchild, Robert M ^a   Furst, Daniel E ^c   Li, Shufeng ^a   Alkassab, Firas ^d,e   Bolster, Marcy B ^f   Csuka, M E ^g   Derk, Chris T ^h   Domsic, Robyn T ⁱ   Fischer, Aryeh ^j   Frech, Tracy M ^k   Gomberg Maitland, Mardi ^l   Gordon, Jessica K ^m   Hinchcliff, Monique ⁿ   Hsu, Vivien ^o   Hummers, Laura K ^p   Khanna, Dinesh ^q   Medsger, Thomas A ⁱ   Molitor, Jerry A ^r   Preston, Ioana R ^s   Schiopu, Elena ^q   Shapiro, Lee ^t   Hant, Faye ^u   Silver, Richard ^u   Simms, Robert ^v   Varga, John ⁿ   Steen, Virginia D ^w   Zamanian, Roham T ^a,x   more..

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF UTAH   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

^m HOSPITAL FOR SPECIAL SURGERY   (United States)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

^o ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^p JOHNS HOPKINS UNIVERSITY   (United States)

^q UNIVERSITY OF MICHIGAN   (United States)

^r UNIVERSITY OF MINNESOTA   (United States)

^s TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t Center for Rheumatology LLP   (United States)

^u MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^v BOSTON UNIVERSITY   (United States)

^w GEORGETOWN UNIVERSITY   (United States)

^x Vera Moulton Wall Center for Pulmonary Vascular Diseases   (United States)

more..

Author keywords

BNP; NT proBNP; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CREATININE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; DISEASE EXACERBATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; REGISTER;

AGED; DISEASE PROGRESSION; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; REGISTRIES; SCLERODERMA, SYSTEMIC;

EID: 85031692578     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. GIORDANO N, MONTELLA A, CORALLO C et al.: Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S182-9
2. IUDICI M, CODULLO V, GIUGGIOLI D et al.: Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clin Exp Rheumatol 2013; 31 (Suppl. 76): S31-36
3. HACHULLA E, GRESSIN V, GUILLEVIN L et al.: Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-800
4. MUKERJEE D, ST GEORGE D, COLEIRO B et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93
5. HUNZELMANN N, GENTH E, KRIEG T et al.: The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008; 47: 1185-92
6. KAWUT SM, TAICHMAN DB, ARCHERCHICKO CL, PALEVSKY HI, KIMMEL SE: Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-50
7. CHUNG L, LIU J, PARSONS L et al.: Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-94
8. CONDLIFFE R, KIELY DG, PEACOCK AJ et al.: Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Critical Care Med 2009; 179: 151-7
9. CHANG B, WIGLEY FM, WHITE B, WISE RA: Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30: 2398-405
10. MATHAI SC, HUMMERS LK, CHAMPION HC et al.: Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-77
11. TYNDALL AJ, BANNERT B, VONK M et al.: Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15
12. STEEN VD, LUCAS M, FERTIG N, MEDSGER TA Jr.: Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol 2007; 34: 2230-5
13. WIGLEY FM, LIMA JA, MAYES M, McLAIN D, CHAPIN JL, WARD-ABLE C: The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52: 2125-32
14. GALIÈ N, RUBIN LJ, HOEPER MM et al.: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-100
15. DENTON CP, HUMBERT M, RUBIN L, BLACK CM: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-40
16. KIM HN, JANUZZI JL Jr.: Natriuretic peptide testing in heart failure. Circulation 2011; 123: 2015-9
17. MUKERJEE D, YAP LB, HOLMES AM et al.: Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97: 1230-6
18. ALLANORE Y, BORDERIE D, AVOUAC J et al.: High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-91
19. HINCHCLIFF M, FISCHER A, SCHIOPU E, STEEN V, for the PHARO S Investigators: Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population. J Rheumatol 2011; 38: 2172-9
20. THAKKAR V, STEVENS WM, PRIOR D et al.: The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2013; 15: R193
21. CAVAGNA L, CAPORALI R, KLERSY C et al.: Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37: 2064-70
22. WILLIAMS MH, HANDLER CE, AKRAM R et al.: Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-94
23. NAGAYA N, NISHIKIMI T, UEMATSU M et al.: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-70
24. NAGAYA N, NISHIKIMI T, OKANO Y et al.: Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-8
25. COGHLAN JG, DENTON CP, GRüNIG E et al.: Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-9
26. McLAUGHLIN VV, ARCHER SL, BADESCH DB et al.: ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619
27. GALIE N, HOEPER MM, HUMBERT M et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). ESC Committee for Practice Guidelines (CPG). Eur Heart J 2009; 30: 2493-537
28. ALLANORE Y, BORDERIE D, MEUNE C et al.: N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003; 48: 3503-8
29. SHAH SJ, THENAPPAN T, RICH S et al.: Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008; 117: 2475-83
30. CHUNG L, DOMSIC RT, LINGALA B et al.: Survival and Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Arthritis Care Res 2014; 66: 489-95
31. KHANNA D, GLADUE H, CHANNICK R et al.: Recommendations for Screening and Detection of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension. Arthritis Rheum 2013; 65: 3194-201